Passage BIO, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Passage BIO, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($7.75M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($9.39M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($15.41M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($19.34M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($15.99M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.71M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($27.11M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($23.86M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($34.34M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($26.70M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($39.54M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($42.81M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($46.92M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($48.44M) | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($38.88M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($28.53M) | Nov 4, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($27.17M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($17.59M) | May 5, 2021 |
| Q1 | 2020 | Dec 31, 2019 | ($7.67M) | May 11, 2020 |
| Q3 | 2020 | Sep 30, 2019 | ($11.39M) | Nov 10, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($8.66M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($10.33M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($16.46M) | May 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($20.70M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($17.38M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.05M) | May 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($28.67M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($25.39M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($35.88M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($27.53M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($39.81M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($42.81M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($47.10M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($48.53M) | Aug 4, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($38.93M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($28.63M) | Nov 4, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($27.30M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($17.91M) | May 5, 2021 |
| Q1 | 2020 | Dec 31, 2019 | ($4.19M) | May 11, 2020 |
| Q3 | 2020 | Sep 30, 2019 | ($11.64M) | Nov 10, 2020 |